BioAtla initiates strategic review to monetize assets; Q4 net loss $9.8M, cash $7.1M

BioAtla, Inc.

Board launched formal process to explore sale, licensing, or other strategic options; Tungsten Advisors engaged.
Net loss Q4 2025: $9.8M versus $14.9M year ago; full year net loss $59.6M.
Cash and equivalents $7.1M at Dec 31, 2025; company expects to extend runway via cost cuts and equity facility.
March 2026 workforce reduction implemented; re-evaluating Phase 1 BA3182 enrollment and Phase 3 ozuriftamab vedotin timeline.
Pre-paid advance agreements fully converted to common stock; no remaining obligations.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BioAtla, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue Collaboration and other revenue was $2.0 million for the fourth quarter and full year 2025, net income Net loss for the fourth quarter of 2025 was $9.8 million, compared to a net loss of $14.9 million for the same period in.

Period: fourth quarter and full year ended December 31, 2025
Revenue: Collaboration and other revenue was $2.0 million for the fourth quarter and full year 2025
Net income: Net loss for the fourth quarter of 2025 was $9.8 million, compared to a net loss of $14.9 million for the same period in
Result: reported results

Exact text from the filing

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and business Highlights – Initiated a formal process to monetize assets – Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights.

View on SEC.gov

Browse all earnings releases →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-134501

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.